VLP Therapeutics, LLC. announced today that it has received a grant for approximately US$960,000 from the Global Health Innovative Technology Fund (“the GHIT Fund”) for early-stage research to develop new vaccines for dengue fever using virus-like particles that would target all four strains of the virus. Dengue fever is one of the world’s most serious public health problems, threatening more than half the world’s population, and infecting 50 to 100 million people every year.
{iframe}http://finance.yahoo.com/news/vlp-therapeutics-receives-grant-global-110000180.html?soc_src=social-sh&soc_trk=ma{/iframe}